U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07783477) titled 'A Study of Armored CAR T Cells in People With Cancer' on Aug. 20.
Brief Summary: The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Neuroendocrine Cancer
Small Cell Lung Cancer
Small Cell Lung Cancer ( SCLC )
Intervention:
DRUG: DLL3-SAVVYZ-IL18 CAR T cell
DLL3-SAVVYZ-IL18 CAR T cell
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Memorial Sloan Kettering Cancer Center
Disclaimer: Curated by HT Syndication....